Clinical Cancer Research

OCT 21, 2026 · JOURNAL ARTICLE

Serial circulating tumour DNA monitoring in first-line advanced NSCLC (COPE): a randomized, two-arm non-comparative phase II trial

Clinical Cancer Research

Abstract Purpose: COPE evaluated serial circulating tumor DNA (ctDNA) profiling with molecular tumor board (MTB) review during first-line therapy for advanced non–small cell lung c

OCT 21, 2026 · JOURNAL ARTICLE

Carboplatin Plus Mirvetuximab Soravtansine In Platinum-Sensitive Ovarian Cancer: A Phase 2 Nonrandomized Clinical Trial

Clinical Cancer Research

Abstract Purpose: Evaluate efficacy and safety of carboplatin plus mirvetuximab soravtansine (MIRV) in folate receptor alpha (FRa)-expressing recurrent PSOC. Patients and Methods:

OCT 19, 2026 · JOURNAL ARTICLE

When the Tumor Disappears, Must the Larynx Follow?

Clinical Cancer Research

REMATCH, a single-institution phase II study, evaluated reduced-volume surgery in patients with locally advanced head and neck cancer responding to neoadjuvant immunochemotherapy.

OCT 15, 2026 · JOURNAL ARTICLE

Anti-TNFR2 antibody BI-1808 induces tumor regression and antitumor T cell immunity through T reg and myeloid cell modulation in patients with solid tumors

Clinical Cancer Research

Abstract Purpose: To clinically evaluate the safety, pharmacodynamic biomarkers, and efficacy of BI-1808, a first-in-class ligand-blocking, Fcγ receptor-engaging anti-TNFR2 antibod

OCT 14, 2026 · JOURNAL ARTICLE

Second- and third-line outcomes after selective RET inhibitor failure in RET fusion-positive metastatic lung cancer: A real-world analysis from the RET-MAP registry

Clinical Cancer Research

Abstract Purpose: Selective RET inhibitors (SRIs) are the first-line standard for RET fusion-positive NSCLC, but no treatment is established after progression. Real-world outcomes

OCT 13, 2026 · JOURNAL ARTICLE

Differential impact of tumor-derived ESR1 mutations on elacestrant benefit in metastatic breast cancer

Clinical Cancer Research

Abstract Background: ESR1 mutations are a well-established mechanism of endocrine therapy resistance in estrogen receptor (ER)-positive metastatic breast cancer and are a biomarker

OCT 8, 2026 · JOURNAL ARTICLE

Drug-specific resistance mechanisms to RET inhibitors in RET fusion-positive NSCLC

Clinical Cancer Research

Abstract Purpose: Ret proto-oncogene (RET) fusions are highly heterogeneous oncogenic drivers occurring in approximately 1-2% of non-small cell lung cancer (NSCLC). While selpercat

OCT 6, 2026 · JOURNAL ARTICLE

Pancreatic Cancer KRAS Breakthrough: Drug Graveyard No More

Clinical Cancer Research

Pancreatic ductal adenocarcinoma (PDAC) remains a highly lethal malignancy and has long been regarded as a therapeutic "drug graveyard", with modest gains from cytotoxic combinatio